Core Insights - SINTX Technologies has received a Notice of Allowance for a patent covering its antipathogenic fabric technology, enhancing its competitive advantage and expanding licensing opportunities in a $30 billion total addressable market [1][6][4] Intellectual Property Expansion - The new patent builds on a previously announced patent for Antipathogenic Fibrous Materials, providing dual coverage for both the material and the processes, which strengthens the company's competitive position [2][4] - The two patent families create a comprehensive IP barrier around SINTX's pathogen-inactivation technology, applicable in various medical and healthcare products [3][4] Market Context - The infection-prevention market is characterized as a significant opportunity, estimated at approximately $30 billion across sectors such as medical textiles, wound management, and filtration [6] - The prevalence of healthcare-associated infections (HAIs) in U.S. hospitals underscores the demand for effective infection-prevention solutions [7] Scientific Validation - Peer-reviewed studies have demonstrated the efficacy of silicon nitride in rapidly inactivating coronaviruses, with lab results showing up to a 99.97% reduction of infectious SARS-CoV-2 [5] Commercial Strategy - SINTX plans to pursue licensing and co-development partnerships across various sectors, leveraging its dual-patent estate to create flexible deal structures [7][4]